このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Apellis Pharmaceuticals マネジメント

マネジメント基準チェック /34

Apellis Pharmaceuticals'の CEO はCedric Francoisで、 Sep2009年に任命され、の在任期間は 14.75年です。の年間総報酬は$ 10.37Mで、 7.1%給与と92.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.51%を直接所有しており、その価値は$ 78.41M 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と8.9年です。

主要情報

Cedric Francois

最高経営責任者

US$10.4m

報酬総額

CEO給与比率	7.1%
CEO在任期間	14.8yrs
CEOの所有権	1.5%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	8.9yrs

経営陣の近況

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Recent updates

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14

Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates

Nov 09

CEO報酬分析

Apellis Pharmaceuticals の収益と比較して、Cedric Francois の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$85m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$2m	US$400k	-US$51m

報酬と市場: Cedricの総報酬 ($USD 10.37M ) は、 US市場 ($USD 8.45M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Cedricの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Cedric Francois (52 yo)

14.8yrs

在職期間

US$10,373,049

報酬

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Cedric Francois	Co-Founder	14.8yrs	US$10.37m	1.51% $ 74.0m
Alec Machiels	Co-Founder & Director	15.4yrs	US$495.96k	0.64% $ 31.3m
Timothy Sullivan	CFO & Treasurer	6.7yrs	US$3.74m	0.084% $ 4.1m
Adam Townsend	Chief Operating Officer	less than a year	US$3.71m	0.023% $ 1.1m
David Watson	General Counsel	10.4yrs	US$4.89m	0.094% $ 4.6m
Caroline Baumal	Chief Medical Officer	1.4yrs	US$4.43m	0.0052% $ 253.1k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	14.8yrs	US$3.08m	0.92% $ 44.9m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	2.8yrs	データなし	0.0085% $ 416.5k
Meredith Kaya	Senior Vice President	no data	データなし	データなし
Karen Lewis	Chief People Officer	4.1yrs	データなし	0.00073% $ 35.7k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2.1yrs	データなし	データなし
Victoria Brown	Senior Vice President	5.3yrs	データなし	0.0031% $ 151.7k

5.3yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: APLSの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Cedric Francois	Co-Founder	14.8yrs	US$10.37m	1.51% $ 74.0m
Alec Machiels	Co-Founder & Director	14.8yrs	US$495.96k	0.64% $ 31.3m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	8.9yrs	データなし	データなし
Lokchung L. Chan	Independent Chairman of the Board	10.9yrs	US$504.08k	0.00056% $ 27.4k
Stephanie O'Brien	Independent Director	10.9yrs	US$488.46k	0.00056% $ 27.4k
Gabriel Coscas	Member of AMD Scientific Advisory Board	8.9yrs	データなし	データなし
Robert Brodsky	Member of PNH Scientific Advisory Board	8.9yrs	データなし	データなし
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	8.9yrs	データなし	データなし
Paul Fonteyne	Independent Director	4.2yrs	US$489.08k	0.0047% $ 229.1k
A. Dunlop	Independent Director	14.3yrs	US$480.96k	0.11% $ 5.3m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	データなし	データなし
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	8.9yrs	データなし	データなし

8.9yrs

平均在職期間

57.5yo

平均年齢

経験豊富なボード: APLSの取締役会は経験豊富であると考えられます ( 8.9年の平均在任期間)。

Apellis Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Recent updates

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

CFO & Treasurer exercised options and sold US$633k worth of stock

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Price target decreased by 9.8% to US$93.23

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

New minor risk - Share price stability

General Counsel notifies of intention to sell stock

Chief People Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Consensus revenue estimates increase by 57%, EPS downgraded

Price target increased by 12% to US$100

Chief Commercial Officer notifies of intention to sell stock

Insufficient new directors

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Chief Commercial Officer notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Co-Founder exercised options to buy US$6.5m worth of stock.

Co-Founder & Director exercised options and sold US$62k worth of stock

Price target increased by 13% to US$85.06

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Co-Founder notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

マネジメント基準チェック /34